I can't say that.... Our experience comes from women's health, and much less in terms of the interaction of different acts.
The most important principle is for mandatory labelling to be at the top of the chain, in terms of sectors that are covered and what's required. I can't speak to the question of the best-placed act, but it can't be used as a reason not to move forward with mandatory labelling. “It would provide little good” is, I think, a very pernicious argument.
There's a whole ingredient transparency movement happening, particularly in the United States. We need to be part of this and work out the best place to put it. From our analysis, working with colleagues, that's in CEPA.